Loading...
榮耀里程2018-11-01T08:48:55+00:00
  • 2018

    • SB05 is awarded: 2018 Taiwan Bio Industry Organization Award- Innovation of the Year.

     

  • 2017

    • Received US FDA and TFDA IND clearance of SB05 to conduct phase 3 pancreatic cancer clinical trail.

     

  • 2016

    • Partnered with Swiss company Y-YBar to develop diagnosis instruments for eye diseases in Taiwan.
    • Publication released from cell lab on Journal of Functional Foods (Vol23).

    • Endo TAG- ®1 is approved to implement phase 3 TNBC clinical trial in Taiwan and Australia.

     

  • 2015

    • Cooperated with National Taiwan University Hospital to establish “AMD Research Center”.
    • Signed co-develop contract (SB04) with AJU PHARM Korea.

    • SB01 phase 2 clinical trial for head and neck cancer was approved by TFDA and FDA.

  • 2014

    • Publish listed in Taiwan OTC stock market in October (code: 4192).

    • Received “The 10th National Innovation Award”.

    • SB05 CTA (IND) received FAMHP approval to conduct phase 3 clinical trial in Belgium.

  • 2013

    • SB04 IND for phase 2/3 clinical trial in Taiwan was approved by TFDA.

    • SB03 received TFDA marketing apporval.

    • SynCoreBio was approved to go public.

     

  • 2012

    • “SynCore Biotechnology” official name registered.

    • SB01 qualified by Ministry of Economic Affairs in biotechnology and new drug development.

    • SB05 developing and marketing rights for phase 3 clinical trial in Asia Pacific were granted from Medigene AG.

    • The “Cross-Strait Cooperation Agreement on Medicine and Public Health Affairs” for SB04 was obtained from TFDA.

  • 2011

    • Collaborate with Medigene AG for the development and deliver rights of Veregen ®(SB03) in Taiwan.

    • SB04 (MC-1101) announced collaboration with MacuCLEAR Inc. for R&D, production , and marketing & sales in Asia and Australia.

     

  • 2010

    • SB01 approved for phase 1 clinical trial by FDA and TFDA.

     

  • 2009


    • Taiwan CDE recognized SB01 as benchmark. The patents were granted in USA and Taiwan.

  • 2008

    • SynCoreBio was established in 2008 as a new drug development company by Sinphar Pharmaceutical Co. Ltd.

    • Partnered with National Health Research Institute(NHRI,Taiwan) on technology transfer of SB01 and SB02.